Theravance Biopharma Inc (0TB) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Theravance Biopharma Inc (0TB) has a cash flow conversion efficiency ratio of -0.028x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-6.51 Million ≈ $-7.61 Million USD) by net assets (€232.68 Million ≈ $272.03 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see how much is Theravance Biopharma Inc worth for the company's overall valuation and market capitalisation.
Theravance Biopharma Inc - Cash Flow Conversion Efficiency Trend (2014–2024)
This chart illustrates how Theravance Biopharma Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Theravance Biopharma Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Theravance Biopharma Inc ranked by their cash flow conversion efficiency. Explore how high is Theravance Biopharma Inc's earnings quality to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
WCON Electronics (Guangdong) Co. Ltd. A
SHE:301328
|
N/A |
|
Geron Corporation
NASDAQ:GERN
|
-0.072x |
|
Wuxi Longsheng Technology Co Ltd
SHE:300680
|
0.055x |
|
Chengdu Guibao Science Tech
SHE:300019
|
0.077x |
|
Heritage Commerce Corp
NASDAQ:HTBK
|
0.028x |
|
Compass Diversified Holdings
NYSE:CODI
|
0.049x |
|
Adlai Nortye Ltd. American Depositary Shares
NASDAQ:ANL
|
4.020x |
|
Cablevision Holding SA
BA:CVH
|
0.093x |
Annual Cash Flow Conversion Efficiency for Theravance Biopharma Inc (2014–2024)
The table below shows the annual cash flow conversion efficiency of Theravance Biopharma Inc from 2014 to 2024. View latest Theravance Biopharma Inc stock price today for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | €175.54 Million ≈ $205.23 Million |
€-11.54 Million ≈ $-13.49 Million |
-0.066x | +48.16% |
| 2023-12-31 | €213.00 Million ≈ $249.01 Million |
€-27.00 Million ≈ $-31.56 Million |
-0.127x | +70.05% |
| 2022-12-31 | €441.80 Million ≈ $516.51 Million |
€-186.99 Million ≈ $-218.61 Million |
-0.423x | -168.94% |
| 2021-12-31 | €-338.57 Million ≈ $-395.83 Million |
€-207.86 Million ≈ $-243.01 Million |
0.614x | -25.53% |
| 2020-12-31 | €-303.75 Million ≈ $-355.12 Million |
€-250.40 Million ≈ $-292.75 Million |
0.824x | -22.53% |
| 2019-12-31 | €-223.84 Million ≈ $-261.69 Million |
€-238.20 Million ≈ $-278.48 Million |
1.064x | -51.36% |
| 2018-12-31 | €-51.59 Million ≈ $-60.31 Million |
€-112.87 Million ≈ $-131.95 Million |
2.188x | +225.33% |
| 2017-12-31 | €115.18 Million ≈ $134.66 Million |
€-201.05 Million ≈ $-235.05 Million |
-1.746x | -517.60% |
| 2016-12-31 | €350.23 Million ≈ $409.46 Million |
€-98.99 Million ≈ $-115.73 Million |
-0.283x | +59.31% |
| 2015-12-31 | €243.06 Million ≈ $284.17 Million |
€-168.86 Million ≈ $-197.41 Million |
-0.695x | -14.94% |
| 2014-12-31 | €289.79 Million ≈ $338.79 Million |
€-175.16 Million ≈ $-204.77 Million |
-0.604x | -- |
About Theravance Biopharma Inc
Theravance Biopharma, Inc., a biopharmaceutical company, develops and commercializes medicines in the United States. It offers YUPELRI, a once-daily, nebulized long-acting muscarinic antagonist for the treatment of chronic obstructive pulmonary disease (COPD). Its late-stage investigational once-daily norepinephrine reuptake inhibitor, Ampreloxetine is in the development for symptomatic neurogeni… Read more